IO Biotech Overview
IO Biotech (IOBT) has a ROE of -9698.02%, below the sector sector average of 11.64%.
Get informed when a big investor buys or sells
+ Follow-9698.02%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
IO Biotech (IOBT) currently reports a ROE of -9698.02%. That is below the sector sector average of 11.64%. Use the charts on this page to explore IO Biotech's ROE history and peer comparisons.
IO Biotech's ROE of -9698.02% is lower than the its sector sector average of 11.64%. That is roughly 83440.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but IO Biotech's current -9698.02% should be judged against industry norms (sector average: 11.64%) and against IOBT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -9698.02%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.64%. From there, open related valuation or income-statement pages for IO Biotech, and consider following IOBT for alerts when major investors trade the stock.
